136 related articles for article (PubMed ID: 30978703)
1. Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer.
Zaballos MA; Acuña-Ruiz A; Morante M; Crespo P; Santisteban P
Endocr Relat Cancer; 2019 Jun; 26(6):R319-R344. PubMed ID: 30978703
[TBL] [Abstract][Full Text] [Related]
2. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
Sáez JM
Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
[TBL] [Abstract][Full Text] [Related]
3. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
4. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
[TBL] [Abstract][Full Text] [Related]
5. Targeting the ERK pathway: novel therapeutics for thyroid cancer.
Williams SF; Smallridge RC
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):199-220. PubMed ID: 15379723
[TBL] [Abstract][Full Text] [Related]
6. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
Melillo RM; Castellone MD; Guarino V; De Falco V; Cirafici AM; Salvatore G; Caiazzo F; Basolo F; Giannini R; Kruhoffer M; Orntoft T; Fusco A; Santoro M
J Clin Invest; 2005 Apr; 115(4):1068-81. PubMed ID: 15761501
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor Lefty.
Miyata N; Azuma T; Hozawa S; Higuchi H; Yokoyama A; Kabashima A; Igarashi T; Saeki K; Hibi T
Pancreas; 2012 Jul; 41(5):745-52. PubMed ID: 22441145
[TBL] [Abstract][Full Text] [Related]
8. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].
Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L
Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683
[TBL] [Abstract][Full Text] [Related]
9. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
10. Sulforaphene Enhances The Efficacy of Photodynamic Therapy In Anaplastic Thyroid Cancer Through Ras/RAF/MEK/ERK Pathway Suppression.
Chatterjee S; Rhee Y; Chung PS; Ge RF; Ahn JC
J Photochem Photobiol B; 2018 Feb; 179():46-53. PubMed ID: 29331658
[TBL] [Abstract][Full Text] [Related]
11. Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.
Lo HW
Curr Cancer Drug Targets; 2010 Dec; 10(8):840-8. PubMed ID: 20718706
[TBL] [Abstract][Full Text] [Related]
12. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
14. Nobiletin induces inhibitions of Ras activity and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling to suppress cell proliferation in C6 rat glioma cells.
Aoki K; Yokosuka A; Mimaki Y; Fukunaga K; Yamakuni T
Biol Pharm Bull; 2013; 36(4):540-7. PubMed ID: 23546290
[TBL] [Abstract][Full Text] [Related]
15. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
16. DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers.
Buffet C; Hecale-Perlemoine K; Bricaire L; Dumont F; Baudry C; Tissier F; Bertherat J; Cochand-Priollet B; Raffin-Sanson ML; Cormier F; Groussin L
PLoS One; 2017; 12(9):e0184861. PubMed ID: 28910386
[TBL] [Abstract][Full Text] [Related]
17. Fibronectin-induced proliferation in thyroid cells is mediated by alphavbeta3 integrin through Ras/Raf-1/MEK/ERK and calcium/CaMKII signals.
Illario M; Cavallo AL; Monaco S; Di Vito E; Mueller F; Marzano LA; Troncone G; Fenzi G; Rossi G; Vitale M
J Clin Endocrinol Metab; 2005 May; 90(5):2865-73. PubMed ID: 15687337
[TBL] [Abstract][Full Text] [Related]
18. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
19. [Intracellular signaling mechanisms in thyroid cancer].
Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
[TBL] [Abstract][Full Text] [Related]
20. MEK in cancer and cancer therapy.
Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
